Summary of Key Points Core Viewpoint - The company Kintor Pharmaceutical Co., Ltd. has been actively repurchasing its shares, indicating a strategy to support its stock price amid recent declines [2][3]. Group 1: Share Buyback Activity - On November 24, Kintor repurchased 360,000 shares at a price range of HKD 15.880 to HKD 16.750, totaling HKD 5.9567 million [2]. - The stock closed at HKD 15.880 on the same day, reflecting a decline of 6.15%, with a total trading volume of HKD 103 million [2]. - Since November 20, the company has conducted share buybacks for three consecutive days, accumulating a total of 763,000 shares repurchased and a total expenditure of HKD 12.914 million, during which the stock price fell by 8.26% [2]. Group 2: Year-to-Date Buyback Summary - Year-to-date, Kintor has executed nine buyback transactions, repurchasing a total of 4.1855 million shares for a cumulative amount of HKD 66.6845 million [3]. - The detailed buyback transactions include various dates, share quantities, and price ranges, showcasing a consistent effort to stabilize the stock price [3].

科济药业-B(02171)发布公告，于2025年11月24日斥资595.67万港元回购36万股。 ...

Group 1 - The company Kintor Pharmaceutical-B (02171.HK) announced a share buyback on November 24, spending HKD 5.957 million to repurchase 360,000 shares [1]

智通财经APP讯，科济药业-B(02171)发布公告，于2025年11月24日斥资595.67万港元回购36万股。 ...

表格類別： 股票 狀態： 新提交 公司名稱： 科濟藥業控股有限公司 呈交日期： 2025年11月24日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02171 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | | | | ...

Group 1 - The core point of the article is that Kexing Pharmaceutical-B has been actively repurchasing its shares, with a total of 382.55 million shares repurchased this year, amounting to 607.28 million HKD [2][3] - On November 21, the company repurchased 235,000 shares at a price range of 16.570 to 17.090 HKD, totaling 3.9829 million HKD, while the stock closed at 16.920 HKD, down 4.14% for the day [2] - Since November 20, the company has conducted share buybacks for two consecutive days, repurchasing a total of 403,000 shares for a cumulative amount of 6.9572 million HKD, during which the stock price has decreased by 2.25% [2][3] Group 2 - The detailed buyback history shows that on November 20, 168,000 shares were repurchased at a maximum price of 17.850 HKD and a minimum price of 17.540 HKD, totaling 2.9744 million HKD [3] - The largest buyback occurred on November 6, with 1.734 million shares repurchased at a maximum price of 15.800 HKD, totaling 26.3078 million HKD [3] - The buyback activity indicates a strategic move by the company to support its stock price amid recent declines [2][3]

Group 1 - The company Kintor Pharmaceutical (02171) announced a share buyback plan, committing to repurchase 235,000 shares at a total cost of HKD 3.9829 million [1]

科济药业-B(02171)发布公告，于2025年11月21日，该公司斥资398.29万港元回购23.5万股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 科濟藥業控股有限公司 呈交日期： 2025年11月21日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02171 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | | 佔有 ...

香港联交所最新数据显示，11月19日，非执行董事郭华清增持科济药业-B(02171)3.65万股，每股作价 17.29港元，总金额约为63.11万港元。增持后最新持股数目约为2.182亿股，持股比例为37.75%。 ...